Skip to main content
. 2018 Mar 5;26(2):297–305. doi: 10.3727/096504017X14980882803151

Figure 3.

Figure 3

MEG3 downregulates miR-184 expression in leukemia. (A) Bioinformatics analysis of MEG3 and miR-184. (B) HL-60 cells were transfected with luciferase reporter plasmid that contained the wild-type or mutant binding site of miR-184 and cotransfected with different levels of the miR-184 mimic for 24 h. Cell lysates were assayed for luciferase activity. (C) The mRNA levels of miR-184 in serum from 57 leukemia patients were assayed by qRT-PCR. (D) The mRNA levels of miR-184 in THP-1, HL-60, CCL-240, and CRL-1582 cells were assayed by qRT-PCR. (E) HL-60 cells were transfected with the LV-MEG3 and/or miR-184 mimic for 24 h, and the mRNA levels of miR-184 were assayed by qRT-PCR. (F) HL-60 cells were transfected with the MEG3 siRNA and/or miR-184 inhibitor for 24 h, and the mRNA levels of miR-184 were assayed by qRT-PCR. All the experiments were repeated at least three times. *p < 0.05, **p < 0.01, ***p < 0.001 versus normal cells or scramble. #p < 0.05 versus miR-184 mimic or inhibitor treated alone.